Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
6 l& M: R6 ^3 ]- Z% Z5 L6 g9 Z
4 S( t/ L) g& S
9 [& P5 r) J* n x; x5 XSub-category:; h# z2 ?2 s0 z) y! ?" G
Molecular Targets
( U0 ]# c. B$ l2 a, U
" E% f! r7 z1 e( ~6 \
6 ^% B# q0 ? d5 p- F+ ECategory:
7 o. j) n# `1 _1 K0 F- p; \8 XTumor Biology
: \; J2 R: k. S- O+ ^. ^* x7 w! r, D# D m* o
% [- {3 W9 _& n3 w& {4 U2 e2 lMeeting:" n6 u& N% b# N& D) u5 K
2011 ASCO Annual Meeting
, {" h& H* D. b1 L6 u- {( Z: s; @
. t% C1 S0 q; _0 P2 r2 \, USession Type and Session Title:2 ]9 t4 ]( M' I) q7 _; T
Poster Discussion Session, Tumor Biology ( T! l' I! I# S+ W! F8 ^
i m8 Z) ?( |5 \4 n
, v6 c& F, Q9 Q2 qAbstract No:
8 h" e9 j9 @6 p& w. d: _10517
J: a9 X9 G) D5 k* b
. m" v: w- Z7 n6 { p% O
; j8 m% J3 \2 _+ [5 g6 V5 c6 [Citation:; R1 D' `! a B" }! d
J Clin Oncol 29: 2011 (suppl; abstr 10517)
. P5 s r2 M+ u. ^: X5 h3 b$ r4 B; q
n' x" |% B. A) R8 W& u+ [$ |3 w
* @0 e) S" w! ~& K; FAuthor(s):
. n+ k5 l _9 |0 {8 n8 o5 t) a, [" ?J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
5 H3 E% R" B" X; D/ O
' ?6 M1 H6 X4 a6 w, h5 p8 m$ F8 o- E! m
/ _$ |. T2 V! U
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
+ q0 ~8 u6 [- f |2 C* p& U5 U( H7 A" F9 I' [
Abstract Disclosures( r: D' h0 u5 L/ @; E6 J6 X
+ }. `$ K o1 R v0 V4 g9 JAbstract:: R7 c/ [: J- D& j! W4 ^
3 o+ A$ ^$ X3 T& |/ B# t
" f* J/ ]5 R! o5 h- B
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.9 a+ S" h+ B, V$ Z
5 O( o2 \7 ^& ?) b- g) P
$ E \% P( p& u, p9 o |
+ ^# r) g$ H* l1 C* t2 ~* P
显身卡
